Table 1. Selected active clinical trials with both upfront and consolidative local ablative therapies for OM-NSCLC.

ClinicalTrials.gov Trial ID	Study design	Patient OM characteristics	Intervention	Primary end point	Study status
NCT03827577 (OMEGA)	Phase III randomized 1:1 parallel assignment	Metachronous and synchronous, 1–3 metastases. Can be enrolled prior or after primary systemic therapy if no progression (Target: 195)	Systemic therapy (platinum doublet chemotherapy or EGFR-TKI or immunotherapy directed by molecular status) ± upfront LAT or LCT consisting of primary resection (if primary in place) and OM LAT with surgery, SABR, or RFA.	OS up to 60 months	Recruiting
NCT02076477 (OITROLC)	Phase III randomized 1:1 parallel assignment	Synchronous, 1–5 metastases (Target: 450)	Upfront LAT with concurrent chemoradiation to all disease sites followed by 2 cycles of platinum-doublet chemotherapy vs. initial 2 cycles of platinum-doublet chemotherapy followed by LCT with chemoradiation	Response rate 3 months after treatment	Recruiting

OM, oligometastatic; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; LAT, local ablative therapies; LCT, local consolidative therapies; OS, overall survival.